Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial
Open Access
- 17 May 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 21 (1), 108
- https://doi.org/10.1186/s13054-017-1695-0
Abstract
Simvastatin therapy for patients with acute respiratory distress syndrome (ARDS) has been shown to be safe and associated with minimal adverse effects, but it does not improve clinical outcomes. The aim of this research was to report on mortality and cost-effectiveness of simvastatin in patients with ARDS at 12 months. This was a cost-utility analysis alongside a multicentre, double-blind, randomised controlled trial carried out in the UK and Ireland. Five hundred and forty intubated and mechanically ventilated patients with ARDS were randomly assigned (1:1) to receive once-daily simvastatin (at a dose of 80 mg) or identical placebo tablets enterally for up to 28 days. Mortality was lower in the simvastatin group (31.8%, 95% confidence interval (CI) 26.1–37.5) compared to the placebo group (37.3%, 95% CI 31.6–43.0) at 12 months, although this was not significant. Simvastatin was associated with statistically significant quality-adjusted life year (QALY) gain (incremental QALYs 0.064, 95% CI 0.002–0.127) compared to placebo. Simvastatin was also less costly (incremental total costs –£3601, 95% CI –8061 to 859). At a willingness-to-pay threshold of £20,000 per QALY, the probability of simvastatin being cost-effective was 99%. Sensitivity analyses indicated that the results were robust to changes in methodological assumptions with the probability of cost-effectiveness never dropping below 90%. Simvastatin was found to be cost-effective for the treatment of ARDS, being associated with both a significant QALY gain and a cost saving. There was no significant reduction in mortality at 12 months, ISRCTN, 88244364. Registered 26 November 2010.Keywords
Funding Information
- Efficacy and Mechanism Evaluation Programme (08/99/08)
- Health Research Board (HRA_POR-2010-131)
This publication has 18 references indexed in Scilit:
- Simvastatin in the Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2014
- Integrating Mortality and Morbidity OutcomesAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Cost–utility analysis conducted alongside randomized controlled trials: Are economic end points considered in sample size calculations and does it matter?Clinical Trials, 2012
- Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trialTrials, 2012
- Beyond MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Two-Year Outcomes, Health Care Use, and Costs of Survivors of Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Variable costs of ICU patients: a multicenter prospective studyIntensive Care Medicine, 2006
- Incidence and Outcomes of Acute Lung InjuryThe New England Journal of Medicine, 2005
- Epidemiology and outcome of acute lung injury in European intensive care unitsIntensive Care Medicine, 2004
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990